WHO says it awaits full clinical data from Merck on antiviral pill molnupiravir

Published: Updated:
Enable Read mode
100% Font Size

The World Health Organization is awaiting full clinical data on the antiviral pill made by Merck & Co Inc to treat mild-to-moderate COVID-19 patients, a WHO spokesperson said on Tuesday, a day after the company said it had applied for US emergency use authorization.

WHO spokesperson Christian Lindmeier, asked at a UN briefing in Geneva about the drug, said: “Indeed, this is an interesting development. We would have to see the full data about it. If it holds true, then it is another weapon in the fight against the COVID-19 pandemic.”

Read the latest updates in our dedicated coronavirus section.

The treatment, molnupiravir, cut the rate of hospitalization and death by 50 percent in a trial of mild-to-moderately ill patients who had at least one risk factor for the disease, according to data released this month.

For the latest headlines, follow our Google News channel online or via the app.

Read more:

Experts predict ‘severe’ flu season once COVID-19 restrictions relaxed

WHO advises additional COVID-19 shot for immunocompromised people

AstraZeneca drug cocktail succeeds in late-stage study to treat COVID-19

Top Content Trending